 |
| ||||||||||||||
 |
||||||||||||||
|
|
 |
| We develop anti-thrombotic molecules as potential therapeutic drugs for coronary artery disease. We perform functional studies to develop monoclonal antibodies and small molecules which could inhibit the interaction of platelets with the vessel wall to prevent occlusion of the coronary artery. |
| * OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989 |